Tuberculosis Research and Treatment / 2016 / Article / Tab 1

Research Article

Impact of WHO 2010 Guidelines on Antiretroviral Therapy Initiation among Patients with HIV-Associated Tuberculosis in Clinics with and without Onsite HIV Services in the Democratic Republic of Congo

Table 1

Numbers of TB cases counseled and tested for HIV by quarter and proportions of HIV+ cases initiated on cotrimoxazole prophylaxis and ART in Kisangani and Kinshasa.

Quarter Number of clinicsTotal TB casesWith known HIV status
(%)
Number tested
(%)
HIV positive
(%)
Initiated on CXT
(%)
Total referred
(%)
Initiated on ART
(%)

Kinshasa
Q4 201020844Na769 (91.1)119 (15.5)106 (89.1)7762 (80.5)
Q1 2011201294Na1221 (94.4)187 (15.3)187 (100.0)119118 (99.2)
Q2 201120125153 (4.2)1150 (96.0)109 (9.5)162 (100.0)9077 (85.6)
Q3 201120135957 (4.2)1244 (95.5)135 (10.9)190 (99.0)13677 (56.6)
Q4 201132133854 (4.0)1164 (90.7)111 (9.5)161 (97.6)8262 (75.6)
Q1 201232205473 (3.6)1822 (92.0)195 (10.7)242 (90.3)12989 (69.0)
Q2 201232222456 (2.5)2067 (95.3)206 (10.0)260 (99.2)167141 (84.4)
Q3 201265236135 (1.5)2239 (96.3)253 (11.3)281 (97.6)212185 (87.3)
Q4 201265269157 (2.1)2596 (98.6)269 (10.4)325 (99.7)233216 (92.7)
Q1 201365277654 (1.9)2559 (94.0)299 (11.7)348 (98.6)274251 (91.6)
Q2 201365272068 (2.5)2518 (94.9)298 (11.8)363 (99.2)280268 (95.7)

Total 6520912507 (2.5)19349 (94.8)2181 (11.3)2625 (97.7)17991546 (85.9)

Kisangani
Q2 2011318913 (6.9)149 (84.7)33 (13.4)44 (95.7)2216 (72.7)
Q3 2011627018 (6.7)248 (98.4)44 (10.5)58 (93.5)2817 (60.7)
Q4 2011625224 (9.5)207 (90.8)53 (14.0)53 (68.8)3216 (50.0)
Q1 2012630536 (11.8)221 (82.2)73 (16.7)69 (63.3)3820 (52.6)
Q2 2012632733 (10.1)229 (77.9)65 (14.0)63 (64.3)4416 (36.4)
Q3 20121337111 (3.0)348 (96.7)66 (15.8)73 (94.8)6043 (58.9)
Q4 20121340620 (4.9)385 (99.7)74 (14.0)93 (98.9)6559 (90.8)
Q1 2013133689 (2.4)350 (97.5)80 (20.3)88 (98.9)7170 (98.6)
Q2 20131350011 (2.2)489 (100.0)78 (13.7)89 (100.0)5854 (93.1)

Total 132988175 (5.9)2626 (94.8)566 (14.9)630 (85.0)418311 (74.4)

Number of clinic contributing data.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.